- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02764931
Gluten-free Oats and Gastrointestinal Health in Coeliac Disease, Part 1
The research aims to investigate the effects of gluten-free oats to the gastrointestinal health in celiac disease patients and healthy subjects. The effects of gluten-free oats on the several intestinal parameters, on the composition of the gut microbiota as well as on the metabolic profile of celiac patients and healthy controls will be studied. The study is divided into two parts.
Part 1 will be conducted as a double-blind, randomized and placebo-controlled cross-over study. Healthy subjects will be recruited to the study. The aim is to recruit 15 participants for the part 1. The study will be conducted with a cross-over setting, where the subjects will go through exposure meals and SmartPill ingestion three times (two different oat products and placebo) in a randomized order. The study meals are identical in appearance and fiber content. After consuming the meal subjects will ingest the SmartPill capsule, which will send data on intestinal pH, pressure and temperature to the external portable device. Before and during the passage of capsule the subjects will fill a symptom and food diary. The capsule will exit the body in 1 to 3 days and the data collected by the external device will be collected and analyzed. Before the oat/placebo exposure the subjects will give a fecal and a blood sample. In addition, 36 hours urine samples will be collected.
In part 2 celiac disease patients, non-celiac gluten sensitive subjects and healthy controls will be recruited and they will be divided into four groups: oat-avoiding celiacs (1), oat-consuming celiacs (2), non-celiac gluten sensitive subjects (3) and healthy controls (4). Recruiting aim for each group is 15 subjects. In addition to dietary data, a blood, and a fecal sample will be collected from the subjects. The gut microbiota will be analyzed from the fecal samples. The metabolic products will be analyzed from the fecal, urine and blood samples. The gut microbiota composition will be analyzed with next-generation DNA sequencing techniques.
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Turku, Finland, 20014
- Department of Biochemistry, University of Turku
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy subjects
- Celiac disease and wheat allergy excluded by antigen test
- Age 18-65
- BMI 18,5 - 30
- Normal liver, thyroid and kidney functions
Exclusion Criteria:
- Pacemaker or other implanted electronical device
- Crohn's disease, ulcerative colitis or acute diverticulitis
- Dysphagia or difficulties with swallowing
- Surgery on the GI tract within the last 3 months
- Intestinal obstruction
- Gastric bezoar
- Severe constipation
- Medication that majorly affects GI tract (e.g. laxatives, antacids)
- Antibiotic treatment within the last 6 months
- Blood donation or participating in a another clinical trial within the last month
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Oat meal 1
A single gluten-free oat containing meal number 1 before ingesting the SmartPill capsule.
Dietary intervention.
Gluten free oats and gastrointestinal health
|
Subjects will be served 3 different test meals in a randomized order in the cross-over design
|
Placebo Comparator: Placebo meal
A single meal which does not contain oats before ingesting the SmartPill capsule.
Dietary intervention: gluten-free oats and gastrointestinal health.
|
Subjects will be served 3 different test meals in a randomized order in the cross-over design
|
Experimental: Oat meal 2
A single gluten-free oat containing meal number 2 before ingesting the SmartPill capsule.
Dietary intervention.
Gluten free oats and gastrointestinal health
|
Subjects will be served 3 different test meals in a randomized order in the cross-over design
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pressure, temperature and pH in the intestinal tract
Time Frame: Day 0-5
|
Pressure, temperature and pH in the intestinal tract as measured by ingestible SmartPill capsule
|
Day 0-5
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gastrointestinal symptoms (self-reported)
Time Frame: Day 0-5
|
Gastrointestinal symptoms (self-reported) as measured by a questionnaire
|
Day 0-5
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KAURA1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Unidentified Gastrointestinal Symptoms Following Gluten-free Oats Consumption
-
University of TurkuCompletedUnidentified Gastrointestinal Symptoms Following Gluten-free Oats ConsumptionFinland
-
University of TurkuCompletedUnidentified Gastrointestinal Discomfort Following Dairy ConsumptionFinland
-
University of TurkuCompletedUnidentified Gastrointestinal Symptoms Following Pulses ConsumptionFinland
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
Biomedal S.L.CompletedMonitoring Adherence to the Gluten-free Diet in Celiac Disease Patients
-
Tampere University HospitalTurku University Hospital; Kuopio University Hospital; Seinajoki Central Hospital and other collaboratorsEnrolling by invitationCeliac Disease | Diet, Gluten-Free | Celiac Disease in Children | Follow-up | Transition of CareFinland
-
University of AlicanteCompletedQuality of Life | Celiac Disease | Exercise | Body Composition | Diet, Gluten-Free | Resistance TrainingSpain
-
Uludag UniversityCompletedCeliac Disease in Adolescents | Gluten-Free Diet in the Covid-19 ProcessTurkey
Clinical Trials on Gluten free oats and gastrointestinal health
-
McMaster UniversityRecruitingCeliac Disease | Gluten Sensitivity | Gluten Enteropathy | Gluten AllergyCanada
-
Acibadem UniversityCompletedHashimoto Disease | Hashimoto ThyroiditisTurkey
-
IRCCS Burlo GarofoloUniversity of Trieste; Azienda Socio Sanitaria Territoriale degli Spedali Civili... and other collaboratorsCompletedGenetic Predisposition to Disease | Celiac DiseaseItaly
-
Tampere University HospitalCompleted
-
Università Politecnica delle MarcheMenarini Group; Associazione Italiana Celiachia (AIC)Completed
-
Mayo ClinicCompletedDiarrhea | Diarrhea Predominant Irritable Bowel SyndromeUnited States
-
McMaster UniversityCompletedIBS - Irritable Bowel SyndromeCanada
-
St. Boniface HospitalManitoba Agri-Health Research NetworkCompleted
-
Skidmore CollegeCompletedObesity | Weight Loss
-
All India Institute of Medical Sciences, New DelhiCompleted